UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEI	TIT		120
SCHEL	JUL	JC.	\mathbf{D}

Under the Securities Exchange Act of 1934 (Amendment No.)*

Catabasis Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, Par Value \$0.001 (Title of Class of Securities)

14875P206 (CUSIP Number)

James J. Moloney Gibson, Dunn & Crutcher LLP 3161 Michelson Drive Irvine, CA 92612 (949) 451-3800

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

 $\label{eq:June 8} June~8,~2021$ (Date of Event Which Requires Filing of This Statement) $\$

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
☐ Rule 13d-1(b)
⊠ Rule 13d-1(c)
☐ Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

		1487	

1.			Reporting Persons.		
	I.R.S.	Ident	ification No. of Above Persons (Entities Only)		
			Funds Management LLC		
2.			Appropriate Box if a Member of a Group (See Instructions)		
	(a) □		(b) □		
_					
3.	SEC U	se O	nly		
4.	Citizer	iship	or Place of Organization		
	D.I				
	Delaw				
		5.	Sole Voting Power		
			0		
	mber of	6.	Shared Voting Power		
_	hares eficially	0.	Shared voting Power		
	ned by		4,092,166		
	Each	7.	Sole Dispositive Power		
	porting	, ·	Sole Dispositive Fower		
	erson		0		
7	With	8.	Shared Dispositive Power		
			4,092,166		
9.	Aggreg	gate .	Amount Beneficially Owned by Each Reporting Person		
	4,092,	166			
10.	Check	if th	e Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)		
11.	Percen	t of (Class Represented by Amount in Row (9)		
		,			
4.5	5.3%(1				
12.	Type o	t Re	porting Person (See Instructions)		
	TΛ				
	IΑ				

		Nο			

1.	Names	of F	Reporting Persons.		
	I.R.S.	Ident	tification No. of Above Persons (Entities Only)		
	F-1		CDVI II C		
2.			SPV I, LLC Appropriate Box if a Member of a Group (See Instructions)		
۷.	(a)		(b)		
	(a) <u>—</u>				
3.	SEC U	se O	nly		
4.	Citizei	ıship	or Place of Organization		
	Dalas				
	Delaw	5.	Sole Voting Power		
		٥.	Sole voting I ower		
Nu	mber of		0		
	hares	6.	Shared Voting Power		
	eficially				
	ned by		0		
	Each porting	7.	Sole Dispositive Power		
	erson		0		
,	With	8.	Shared Dispositive Power		
			0		
9.	Aggre	gate 1	Amount Beneficially Owned by Each Reporting Person		
	0				
10.	·				
10.	Gileen		21-288-Educe Innount in 110 ii (b) Ziteladeo Gertain onareo (Gee Instructiono)		
11.	Percer	t of (Class Represented by Amount in Row (9)		
	0.00//	`			
12.	0.0%(1		porting Person (See Instructions)		
14.	туре с	ı ive	horring I erson (see insuractions)		
	00				

		1487	

1.					
	I.R.S.	Ident	tification No. of Above Persons (Entities Only)		
			SPV II, LLC		
2.			Appropriate Box if a Member of a Group (See Instructions)		
	(a) □		(b) □		
3.	SEC U	[co ()	nly		
٥.	SEC C	36 0	nny		
4.	Citizer	ıship	or Place of Organization		
	Delaw				
		5.	Sole Voting Power		
			0		
	mber of hares	6.	Shared Voting Power		
	nares eficially	0.	Shared voting Lower		
	ned by		858,166		
	Each	7.	Sole Dispositive Power		
	porting				
	erson		0		
'	With	8.	Shared Dispositive Power		
			050.466		
0	Λ		858,166		
9.	Aggreg	gate .	Amount Beneficially Owned by Each Reporting Person		
	858,16	6			
10.			e Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)		
11.	Percen	t of (Class Represented by Amount in Row (9)		
	1.1%(1	.)			
12.			porting Person (See Instructions)		
,	-J F - 0				
	00				

⁽¹⁾ Calculated based on 76,948,803 shares of the Issuer's Common Stock outstanding, as disclosed in the amended Current Report on Form 8-K filed by the Issuer with the Securities and Exchange Commission on June 10, 2021.

		1487	

1.			Reporting Persons	
	I.R.S.	Ident	ification No. of Above Persons (Entities Only)	
			Healthcare Fund GP LLC	
2.			Appropriate Box if a Member of a Group (See Instructions)	
	(a) □		(b) □	
_				
3.	SEC U	se O	nly	
4	C :.:	1.		
4.	Citizer	ısnıp	or Place of Organization	
	Delaw	240		
	Delaw	5.	Sole Voting Power	
		٥.	Sole voling rower	
NT	h f		0	
	mber of hares	6.	Shared Voting Power	
_	eficially			
	ned by		271,000	
	Each	7.	Sole Dispositive Power	
	porting			
	erson		0	
,	With	8.	Shared Dispositive Power	
			271,000	
9.	Aggreg	gate .	Amount Beneficially Owned by Each Reporting Person	
10	271,00			
10.	Check	if th	e Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)	
11.		t of (Class Represented by Amount in Row (9)	
11.	rereen	l OI v	Edds Represented by Ambunt in Now (5)	
	0.4%(1	.)		
12.			porting Person (See Instructions)	
	00			

		1487	

1.	. Names of Reporting Persons				
	I.R.S.	Ident	tification No. of Above Persons (Entities Only)		
			Healthcare Fund II GP LLC		
2.			Appropriate Box if a Member of a Group (See Instructions)		
	(a) □		(b) □		
3.	SEC U	se O	only		
4.	Citizer	ıship	or Place of Organization		
	Delaw	are			
		5.	Sole Voting Power		
Nui	mber of		0		
S	hares	6.	Shared Voting Power		
Ben	eficially				
Ow	ned by		2,963,000		
	Each	7.	Sole Dispositive Power		
	porting				
	erson		0		
'	With	8.	Shared Dispositive Power		
			2,963,000		
9.	Aggreg	gate .	Amount Beneficially Owned by Each Reporting Person		
	2,963,0				
10.	Check	if th	e Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)		
	_				
11.	Percen	t of (Class Represented by Amount in Row (9)		
	3.9%(1				
12.	Type o	f Re	porting Person (See Instructions)		
	00				

(a) Name of Issuer Catabasis Pharmaceuticals, Inc. (b) Address of Issuer's Principal Executive Offices 100 High Street, 28th Floor, Boston, MA 02110 Item 2. Name of Person(s) Filing: (a) (A) Fairmount Funds Management LLC (B) Fairmount SPV I, LLC (C) Fairmount SPV II, LLC (D) Fairmount Healthcare Fund GP LLC (E) Fairmount Healthcare Fund II GP LLC Address of Principal Business Office or, if none, Residence: (b) (A) 2001 Market St., Suite 2500, Philadelphia, PA 19103 (B) 2001 Market St., Suite 2500, Philadelphia, PA 19103 (C) 2001 Market St., Suite 2500, Philadelphia, PA 19103 (D) 2001 Market St., Suite 2500, Philadelphia, PA 19103 (E) 2001 Market St., Suite 2500, Philadelphia, PA 19103 Citizenship: (c) (A) Delaware (B) Delaware (C) Delaware (D) Delaware (E) Delaware

Item 1.

(d)

(e)

Title of Class of Securities:

14875P206

CUSIP Number:

Common Stock, Par Value \$0.001

No	t app	licable.
(a)		Broker or dealer registered under section 15 of the Act (15 U.S.C. 780);
(b)		Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)		Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)		Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)		An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
(f)		An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
(g)		A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
(h)		A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)		A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)		A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
(k)		Group, in accordance with $\$240.13d-1(b)(1)(ii)(K)$. If filing as a non-U.S. institution in accordance with $\$240.13d-1(b)(1)(ii)(J)$, please specify the type of institution:

If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

Item 3.

Item 4. Ownership

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

(a), (b), and (c)

Reporting Persons*	Number of Shares With Sole Voting and Dispositive Power	V	Number of Shares With Shared Voting and Dispositive Power	Aggregate Number of Shares Beneficially Owned	Percentage of Class Beneficially Owned**
Fairmount Funds Management LLC		0	4,092,166	4,092,166	5.3%
Fairmount SPV I, LLC		0	0	0	0.0%
Fairmount SPV II, LLC		0	858,166	858,166	1.1%
Fairmount Healthcare Fund GP LLC		0	271,000	271,000	0.4%
Fairmount Healthcare Fund II GP LLC		0	2,963,000	2,963,000	3.9%

^{*} The above figures reflect the most recent beneficial ownership for the Reporting Persons above as of June [10], 2021.

Item 5. Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following \Box .

Item 6. Ownership of More than Five Percent on Behalf of Another Person

Not applicable.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person

Not applicable.

Item 8. Identification and Classification of Members of the Group

Not applicable.

Item 9. Notice of Dissolution of Group

Not applicable.

^{**} The percentages reported above are calculated based on 76,948,803 shares of the Issuer's Common Stock outstanding as of June 10, 2021. Percentages shown above subject to rounding adjustments.

Item 10. Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

Signature

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: June 17, 2021

FAIRMOUNT FUNDS MANAGEMENT LLC

By: Name: Title:	/s/ Peter Harwin Peter Harwin Managing Member	/s/ Tomas Kiselak Tomas Kiselak Managing Member					
FAIRMOUNT SPV I, LLC							
By:	/s/ Peter Harwin	/s/ Tomas Kiselak					
Name:	Peter Harwin	Tomas Kiselak					
Title:	Managing Member	Managing Member					
FAIRMOUNT SPV II, LLC							
By:	/s/ Peter Harwin	/s/ Tomas Kiselak					
Name:	Peter Harwin	Tomas Kiselak					
Title:	Managing Member	Managing Member					
FAIRMOUNT HEALTHCARE FUND GP LLC							
By:	/s/ Peter Harwin	/s/ Tomas Kiselak					
Name:	Peter Harwin	Tomas Kiselak					
Title:	Managing Member	Managing Member					
FAIRMOUNT HEALTHCARE FUND II GP LLC							
By:	/s/ Peter Harwin	/s/ Tomas Kiselak					
Name:	Peter Harwin	Tomas Kiselak					
Title:	Managing Member	Managing Member					